# Enliven Therapeutics, Inc.: Form SCHEDULE 13D/A, filed Jun 17, 2025

- Company: [Enliven Therapeutics, Inc.](/companies/elvn.md) (CIK 1672619)
- Form: SCHEDULE 13D/A
- Filed: 2025-06-17
- Accepted by EDGAR: Jun 17, 2025, 17:30 ET
- Period: not reported
- Accession: 0000947871-25-000616
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1672619/000094787125000616/xslSCHEDULE_13D_X01/primary_doc.xml
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1672619/000094787125000616/

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1672619/000094787125000616/xslSCHEDULE_13D_X01/primary_doc.xml

Filed Jun 17, 2025.
Source: SEC EDGAR, the filing index for accession 0000947871-25-000616. Last ingested by Listed: Nov 5, 2026, 17:49 ET. No prices; not investment advice.